End–to–End Automation and a Miniaturized DOE for a 384–Well ELISA: A Flexible Robotic Approach for Vaccine Development
Vaccines · 15.11.2026 · 14 (11) · 984
DOI: 10.3390/vaccines14110984 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 15.11.2026. Verfasst von Aleksandr Treyer und 4 weiteren Autor:innen. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Merck Sharp & Dohme LLC.
Abstract (Originalsprache)
Background/Objectives: Vaccine potency assays are critical to evaluate the identity, integrity, and stability of formulations, attributes that must be controlled during pharmaceutical development and manufacturing to ensure efficacy. Enzyme–linked immunosorbent assays (ELISAs) are widely utilized for vaccine potency testing due to their high sensitivity and specificity. However, conventional manual ELISA workflows are labor–intensive, time–consuming, and susceptible to operator variability, and they pose challenges for scalability in fast–paced and commercially driven vaccine manufacturing environments. This study aimed to develop and validate a fully automated 384–well ELISA platform to improve the throughput and efficiency of potency testing for multivalent vaccines.
Methods
An end–to–end workflow was established using liquid–handling robotics to scale throughput beyond the typical 96–well format to a miniaturized 384–well format. An Excel–based data integration system automated data processing, analysis and reporting. A miniaturized, single–plate design–of–experiments (DOE) approach was used to optimize assay conditions for additional vaccine types.
Results
The automated platform increased assay throughput and reduced hands–on time while meeting validation requirements for the evaluated performance characteristics. Integrated data processing reduced manual intervention and streamlined analysis and reporting. The single–plate DOE approach enabled rapid optimization of potency assays for additional vaccine types, supporting efficient method development within the multivalent vaccine program.
Conclusions
The automated 384–well ELISA platform provides a scalable approach to multivalent vaccine potency testing, improving throughput and efficiency while maintaining assay performance.
Förderung
- Merck Sharp & Dohme LLC
Zitieren
APA
Treyer, A., Xin, W., Lavrich, D., Loughney, J. W., & Bowman, A. (2026). End–to–End Automation and a Miniaturized DOE for a 384–Well ELISA: A Flexible Robotic Approach for Vaccine Development. Vaccines, 14(11), 984. https://doi.org/10.3390/vaccines14110984
Vancouver
Treyer A, Xin W, Lavrich D, Loughney JW, Bowman A. End–to–End Automation and a Miniaturized DOE for a 384–Well ELISA: A Flexible Robotic Approach for Vaccine Development. Vaccines. 2026;14(11):984. doi:10.3390/vaccines14110984
BibTeX
@article{Treyer2026,
author = {Treyer, Aleksandr and Xin, Weiyue and Lavrich, David and Loughney, John W. and Bowman, Amy},
title = {End–to–End Automation and a Miniaturized DOE for a 384–Well ELISA: A Flexible Robotic Approach for Vaccine Development},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {984},
doi = {10.3390/vaccines14110984}
}
EUVIMED